Heart failure with preserved ejection fraction (HFpEF) is increasing in incidence and has a higher prevalence compared with heart failure with reduced ejection fraction. So far, no effective treatment of HFpEF is available, due to its complex underlying pathophysiology and clinical heterogeneity. This article aims to provide an overview and a future perspective of transcriptomic biomarker research in HFpEF. Detailed characterisation of the HFpEF phenotype and its underlying molecular pathomechanisms may open new perspectives regarding early diagnosis, improved prognostication, new therapeutic targets and tailored therapies accounting for patient heterogeneity, which may improve quality of life. A combination of cross-sectional and longitudinal study designs with sufficiently large sample sizes are required to support this concept.
%0 Journal Article
%1 Rosch2020-bi
%A Rosch, Sebastian
%A Rommel, Karl-Philipp
%A Scholz, Markus
%A Thiele, Holger
%A Lurz, Philipp
%D 2020
%I Radcliffe Group Ltd
%J Card. Fail. Rev.
%K Heart LIFE-Heart; RNA; blood cells; ejection expression; failure fraction; gene mononuclear peripheral preserved transcriptome with
%P e24
%T Transcriptomic research in heart failure with preserved ejection fraction: Current state and future perspectives
%V 6
%X Heart failure with preserved ejection fraction (HFpEF) is increasing in incidence and has a higher prevalence compared with heart failure with reduced ejection fraction. So far, no effective treatment of HFpEF is available, due to its complex underlying pathophysiology and clinical heterogeneity. This article aims to provide an overview and a future perspective of transcriptomic biomarker research in HFpEF. Detailed characterisation of the HFpEF phenotype and its underlying molecular pathomechanisms may open new perspectives regarding early diagnosis, improved prognostication, new therapeutic targets and tailored therapies accounting for patient heterogeneity, which may improve quality of life. A combination of cross-sectional and longitudinal study designs with sufficiently large sample sizes are required to support this concept.
@article{Rosch2020-bi,
abstract = {Heart failure with preserved ejection fraction (HFpEF) is increasing in incidence and has a higher prevalence compared with heart failure with reduced ejection fraction. So far, no effective treatment of HFpEF is available, due to its complex underlying pathophysiology and clinical heterogeneity. This article aims to provide an overview and a future perspective of transcriptomic biomarker research in HFpEF. Detailed characterisation of the HFpEF phenotype and its underlying molecular pathomechanisms may open new perspectives regarding early diagnosis, improved prognostication, new therapeutic targets and tailored therapies accounting for patient heterogeneity, which may improve quality of life. A combination of cross-sectional and longitudinal study designs with sufficiently large sample sizes are required to support this concept.},
added-at = {2024-09-10T11:54:51.000+0200},
author = {Rosch, Sebastian and Rommel, Karl-Philipp and Scholz, Markus and Thiele, Holger and Lurz, Philipp},
biburl = {https://puma.scadsai.uni-leipzig.de/bibtex/25c1074e0a106dc3640c96a86f5e69ba6/scadsfct},
copyright = {https://creativecommons.org/licenses/by-nc/4.0/legalcode},
interhash = {4808d1ed23f7e4e9e05278c6d97f9846},
intrahash = {5c1074e0a106dc3640c96a86f5e69ba6},
journal = {Card. Fail. Rev.},
keywords = {Heart LIFE-Heart; RNA; blood cells; ejection expression; failure fraction; gene mononuclear peripheral preserved transcriptome with},
language = {en},
month = mar,
pages = {e24},
publisher = {Radcliffe Group Ltd},
timestamp = {2024-09-10T11:54:51.000+0200},
title = {Transcriptomic research in heart failure with preserved ejection fraction: Current state and future perspectives},
volume = 6,
year = 2020
}
